These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
223 related articles for article (PubMed ID: 30482191)
1. Does glucagon have a positive inotropic effect in the human heart? Hernández-Cascales J Cardiovasc Diabetol; 2018 Nov; 17(1):148. PubMed ID: 30482191 [TBL] [Abstract][Full Text] [Related]
2. [Calcium sensitizers--a new group of drugs that increase myocardium contractility]. Laine M; Lehtonen L; Nieminen MS Duodecim; 2000; 116(20):2181-3. PubMed ID: 12017622 [No Abstract] [Full Text] [Related]
3. Levosimendan in patients with low-output heart failure: lessons from the LIDO trial. Follath F Ital Heart J; 2003 May; 4 Suppl 2():34S-38S. PubMed ID: 14635368 [TBL] [Abstract][Full Text] [Related]
4. Inotropes. Francis GS; Bartos JA; Adatya S J Am Coll Cardiol; 2014 May; 63(20):2069-2078. PubMed ID: 24530672 [TBL] [Abstract][Full Text] [Related]
5. Will long-acting glucagon-like peptide-1 analogues recapitulate our agonizing experience with cyclic AMP-dependent positive inotropic agents in heart failure? Packer M Eur J Heart Fail; 2018 Apr; 20(4):627-629. PubMed ID: 29082598 [No Abstract] [Full Text] [Related]
11. Inotropic drugs for treatment of the failing heart. Maskin CS; Le Jemtel TH; Sonnenblick EH Cardiovasc Clin; 1984; 14(3):1-17. PubMed ID: 6327040 [No Abstract] [Full Text] [Related]
12. New positive inotropic agents in the treatment of congestive heart failure. Mechanisms of action and recent clinical developments. 1. Colucci WS; Wright RF; Braunwald E N Engl J Med; 1986 Jan; 314(5):290-9. PubMed ID: 2867470 [No Abstract] [Full Text] [Related]
13. Na+ channel activators as positive inotropic agents for the treatment of chronic heart failure. Flesch M; Erdmann E Cardiovasc Drugs Ther; 2001 Sep; 15(5):379-86. PubMed ID: 11855656 [TBL] [Abstract][Full Text] [Related]
14. The use of inotropic agents in acute and chronic congestive heart failure. Sanders MR; Kostis JB; Frishman WH Med Clin North Am; 1989 Mar; 73(2):283-314. PubMed ID: 2645478 [TBL] [Abstract][Full Text] [Related]
15. Do positive inotropic agents adversely affect the survival of patients with chronic congestive heart failure? II. Protagonist's viewpoint. Packer M J Am Coll Cardiol; 1988 Aug; 12(2):562-6. PubMed ID: 3392349 [No Abstract] [Full Text] [Related]
16. Effects of zacopride, a moderate I Elnakish MT; Canan BD; Kilic A; Mohler PJ; Janssen PM Pharmacol Res; 2017 Jan; 115():309-318. PubMed ID: 27914945 [TBL] [Abstract][Full Text] [Related]
17. Stage-dependent benefits and risks of pimobendan in mice with genetic dilated cardiomyopathy and progressive heart failure. Nonaka M; Morimoto S; Murayama T; Kurebayashi N; Li L; Wang YY; Arioka M; Yoshihara T; Takahashi-Yanaga F; Sasaguri T Br J Pharmacol; 2015 May; 172(9):2369-82. PubMed ID: 25560565 [TBL] [Abstract][Full Text] [Related]
18. Bisoprolol inhibits sodium current in ventricular myocytes of rats with diastolic heart failure. Tang HF; Wu SL; Deng CY; Zhang WC; Kuang SJ Clin Exp Pharmacol Physiol; 2007 Aug; 34(8):714-9. PubMed ID: 17600546 [TBL] [Abstract][Full Text] [Related]
19. Abnormal intracellular calcium handling, a major cause of systolic and diastolic dysfunction in ventricular myocardium from patients with heart failure. Morgan JP; Erny RE; Allen PD; Grossman W; Gwathmey JK Circulation; 1990 Feb; 81(2 Suppl):III21-32. PubMed ID: 2153479 [TBL] [Abstract][Full Text] [Related]